ROR1

ROR1

ROR1 Molekülinformation

Molecule Name
Inactive tyrosine-protein kinase transmembrane receptor ROR1
Molekülalias
ROR1,NTRKR1
Drug Development Progress
Anzahl der klinischen Arzneimittel23
Anzahl der inverkehr gebrachten Arzneimittel0
Höchste Forschungs- und EntwicklungsphasePhase 3 Clinical
Target-Alias
EC 2.7.10.1,Inactive tyrosine-protein kinase transmembrane receptor ROR1,NTRKR1,ROR1,Receptor Tyrosine Kinase Like Orphan Receptor 1,Neurotrophic Tyrosine Kinase, Receptor-Related 1,DJ537F10.1,ROR-1
Molekülhintergrund
Tyrosine-protein kinase transmembrane receptor ROR1 is also known as Neurotrophic tyrosine kinase, receptor-related 1 (NTRKR1), which belongs to the protein kinase superfamily or tyr protein kinase family or ROR subfamily. ROR1 contains 1 FZ (frizzled) domain, 1 Ig-like C2-type (immunoglobulin-like) domain, 1 kringle domain, 1 protein kinase domain. ROR1 is expressed at high levels during early embryonic development. The expression levels drop strongly around day 16 and there are only very low levels in adult tissues. Isoform Short is strongly expressed in fetal and adult CNS and in a variety of human cancers, including those originating from CNS or PNS neuroectoderm. ROR1 could interact with casein kinase 1 epsilon (CK1ε) to activate phosphoinositide 3-kinase-mediated AKT phosphorylation and cAMP-response-element-binding protein (CREB), which was associated with enhanced tumor-cell growth.

ROR1 Produktliste

Species
  • Human / Cynomolgus / Rhesus macaque(10)
  • Human(6)
  • Mouse(4)
  • Canine(1)
  • Rat(1)
Tag
  • His Tag(13)
  • Fc Tag(3)
  • Fc Tag & Avi Tag(2)
  • His Tag & Avi Tag(2)
  • Avi Tag(1)
  • Mouse IgG Fc Tag(1)
Host
  • HEK293(22)
Conjugate
  • Unconjugated(12)
  • Biotin-labeled(5)
  • FITC Labeled(2)
  • PE Labeled(2)
  • APC Labeled(1)
Grade
  • RUO(22)
Low Endotoxin
  • Yes(1)
  • No(21)
MoleculeCat. No.Product NameArtHostStructurePurityActivitySize&PriceAdd to Cart
ROR1
Human / Cynomolgus / Rhesus macaque ROR1 Protein, His Tag
Human / Cynomolgus / Rhesus macaque
HEK293
MALSSDS-PAGE
SPR

$1350.00

250ug
ROR1
Human / Cynomolgus / Rhesus macaque ROR1 Protein, His Tag, low endotoxin (Mass Spec & MALS verified)
Human / Cynomolgus / Rhesus macaque
HEK293
MALSSDS-PAGE
ELISASPRBLIFlow

$470.00

100ug
ROR1
APC-Labeled Human ROR1 Protein, His TagStar Staining
Human
HEK293
Flow

$360.00

25tests
ROR1
PE-Labeled Human ROR1 Protein, His Tag (Site-specific conjugation)
Human
HEK293
Flow

$360.00

25tests
ROR1
Human / Cynomolgus / Rhesus macaque ROR1 (308-395, Kringle domain) Protein, His Tag (MALS verified)
Human / Cynomolgus / Rhesus macaque
HEK293
MALSSDS-PAGE

$420.00

50ug
ROR1
HOTAvitag
RO1-H82E6
Biotinylated Human / Cynomolgus / Rhesus macaque ROR1 Protein, His,Avitag™ (MALS verified)
Human / Cynomolgus / Rhesus macaque
HEK293
MALSSDS-PAGE
ELISASPRBLIFlow

$470.00

25ug
ROR1
Canine ROR1 Protein, His Tag (MALS verified)
Canine
HEK293
MALSSDS-PAGE

$360.00

100ug
ROR1
Human / Cynomolgus / Rhesus macaque ROR1 (39-151, Ig-like domain) Protein, His Tag (MALS verified)
Human / Cynomolgus / Rhesus macaque
HEK293
MALSSDS-PAGE
ELISAFlow

$380.00

50ug
ROR1
Human / Cynomolgus / Rhesus macaque ROR1 (165-305, Frizzled domain) Protein, His Tag (MALS verified)
Human / Cynomolgus / Rhesus macaque
HEK293
MALSSDS-PAGE

$380.00

50ug
ROR1
Human / Cynomolgus / Rhesus macaque ROR1 Protein, Fc Tag (MALS verified)
Human / Cynomolgus / Rhesus macaque
HEK293
MALSSDS-PAGE
ELISABLI

$260.00

200ug
You Have Viewed 1-10 Of 22 Results
  • 1
  • 2
  • 3

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity

Antikörperprojekt-Handelsplattform

ProjektnameProjektphaseMolekültypMolekülquelleKrankheitsgebietIndikationen
ROR1 mAb - 01LeadMonoclonalFull HumanHematological Malignancy,AutoImmunitySolid tumor,Blood tumor
Projektname
ROR1 mAb - 01
Projektphase
Lead
Molekültyp
Monoclonal
Molekülquelle
Full Human
Krankheitsgebiet
Hematological Malignancy,AutoImmunity
Indikationen
Solid tumor,Blood tumor
Resources

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
Zilovertamab vedotinMK-2140; VLS-101Phase 3 ClinicalVelosbio Inc
Breast Neoplasms; Burkitt Lymphoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Hematologic Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, T-Cell; Neoplasms; Neuroblastoma; Ovarian Neoplasms; Pancreatic Neoplasms; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Richter's Syndrome; Sarcoma, Ewing; Stomach Neoplasms; Triple Negative Breast Neoplasms; Waldenstrom Macroglobulinemia
Details
B-013B-013; B013Phase 3 ClinicalShanghai Crosslink Pharmaceutical R & D Co Ltd
Fallopian Tube Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Triple Negative Breast Neoplasms
Details
ZilovertamabUC-961Phase 2 ClinicalUniversity Of California San Diego
Breast Neoplasms; Immune System Diseases; Immunoproliferative Disorders; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphatic Diseases; Lymphoma; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Prostatic Neoplasms, Castration-Resistant
Details
EMB-07EMB-07Phase 2 ClinicalShanghai Epimab Biotherapeutics, Inc
Adenocarcinoma of Lung; Colorectal Neoplasms; Lymphoma; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Neoplasms
Details
EB-DT-CAR-NKEB-DT-CAR-NKPhase 2 ClinicalBeijing Biotech
Breast Neoplasms; Triple Negative Breast Neoplasms
Details
NVG-222NVG-222Phase 2 ClinicalNovalGen Ltd
Hematologic Neoplasms; Neoplasms
Details
HDM-2005HDM2005; HDM-2005Phase 2 ClinicalHangzhou Zhongmei Huadong Pharmaceutical Co Ltd
Hematologic Neoplasms; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Neoplasms; Solid tumours
Details
NebratamigGNC-035Phase 2 ClinicalSichuan Baili Pharmaceutical Co Ltd
Breast Neoplasms; Hematologic Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Metastatic breast cancer; Solid tumours
Details
HG-030HG-030Phase 1 ClinicalHitgen Inc
Solid tumours
Details
anti-ROR1 CAR T-cell therapy (Fred Hutchinson Cancer Research Center/NCI)Phase 1 ClinicalNational Cancer Institute
Neoplasms
Details
PB-004PB004; PBA-0405; PB004 PureBIKE; PB-004Phase 1 ClinicalPure Biologics SA
Sarcoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms
Details
PRGN-3007PRGN-3007Phase 1 ClinicalPrecigen Inc
Hematologic Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Solid tumours; Triple Negative Breast Neoplasms
Details
RD-14RD-14; RD-14-01; CTE001; RD14-01Phase 1 ClinicalNanjing Bioheng Biotech Co Ltd
Breast Neoplasms; Lymphoma, Non-Hodgkin; Ovarian Neoplasms
Details
NEOK-001NEOK001; NEOK-001; ABL206; ABL-206Phase 1 ClinicalAbl Bio Inc
Solid tumours
Details
BR-111BR-111Phase 1 ClinicalZhejiang BioRay Biopharmaceuticals Co Ltd
Neoplasms
Details
SYS-6005RB-164; RB164; SYS6005Y; SYS-6005Phase 1 ClinicalCSPC Pharmaceutical Group Ltd
Hematologic Neoplasms; Leukemia, B-Cell; Lymphoma, B-Cell; Neoplasms; Solid tumours
Details
TQB-2101TQB2101; TQB-2101Phase 1 ClinicalNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group
Breast Neoplasms; Colorectal Neoplasms; Hematologic Neoplasms; Lung Neoplasms; Neoplasms
Details
ZPC-21ZPC-21; IM-1021Phase 1 ClinicalZentalis Pharmaceuticals Inc
Hematologic Neoplasms; Neoplasms; Solid tumours
Details
BR-111ABR-111A; BR111A; BR-111-APhase 1 ClinicalZhejiang BioRay Biopharmaceuticals Co Ltd
Hematologic Diseases; Neoplasms; Solid tumours
Details
LYL-797LYL-797Phase 1 ClinicalLyell Immunopharma Inc
Carcinoma, Non-Small-Cell Lung; Solid tumours; Triple Negative Breast Neoplasms
Details
NVG-111NVG-111Phase 1 ClinicalNovalGen Ltd
Carcinoma, Non-Small-Cell Lung; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Melanoma
Details
LCB-71CS-5001; LCB-71; ABL-202; ROR1-pPBDPhase 1 ClinicalAbl Bio Inc, Legochem Biosciences Inc
Hematologic Neoplasms; Lymphoma; Lymphoma, B-Cell; Solid tumours
Details
SIM-201SIM-201; SIM-0201Phase 1 ClinicalJiangsu Simcere Pharmaceutical Co Ltd
Solid tumours
Details
Customer Reviews